Harvoni US sales dip reflects progress in treating sickest patients, Gilead says
This article was originally published in Scrip
You may also be interested in...
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.